Charcot 2022 Symposium: Brain Preservation and Cognition in MS - European Medical Journal

Charcot 2022 Symposium: Brain Preservation and Cognition in MS


This information is for Healthcare Professionals only.

This promotional video is organised and funded by Bristol Myers Squibb.

Click here for Prescribing Information

Brain Preservation and Cognition in MS: MRI Biomarkers, Early Awareness and the Role of S1P Receptor Modulators, a BMS-promotional Symposium Charcot 2022, highlights new MRI biomarkers of brain atrophy, the importance of early intervention on cognitive outcomes in MS and the role of S1P receptor modulators in MS.

Prof. Matilde Inglese reviews new MRI biomarkers and shows that these markers can demonstrate acute and chronic inflammation, tissue destruction and microstructural abnormalities in the brain and spinal cord of MS patients. She goes on to show that brain atrophy begins early in MS and continues throughout its course, that loss of deep gray matter is associated with disability accumulation, and that advanced MRI techniques provide novel information on microstructural brain pathology in MS.

Prof. Roberta Lanzillo provides an overview of early intervention with high-efficacy DMTs in MS care, showing that this can improve cognitive outcomes. Prof. Lanzillo reviews how cognitive impairment interferes with the performance of daily activities for patients with MS, and that thalamic volume is clearly associated with the risk of cognitive decline in MS.

The Moderator, Prof. Eleonora Cocco, reviews of how early ozanimod use can provide benefits, especially in patients with preserved brain volume. Ozanimod can reduce MS relapses and up to 80% of patients continuously treated with ozanimod had low rates of whole brain volume loss after 6 years.1,2

A very interesting question and answer period completes the Symposium.

IMM-GB-2300293 | Date of Prep: July 2023
Primary Endpoint Data
Safety and Tolerability Profile

Adverse events should be reported. Reporting forms and information can be found via:
Great Britain & Northern Ireland – The Yellow Card Scheme at: or search for MHRA Yellow Card in the Goggle Play or
Apple App store;
Ireland – HPRA Pharmacovigilance at
Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or
08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland).
  1. Brochet B, et al. Proportion of relapsing MS patients with low vs high annualized whole brain volume atrophy rates after 5–6 years of ozanimod and relationship to cognitive processing speed. Poster presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 26–28 October 2022; hybrid conference, Amsterdam, Netherlands.
  2. DeLuca, J., Arnold, D., Hartung, H. P., Kappos, L., Vaile, J., Cheng, C. Y., Pachai, C., Brochet, B. (2022). Positive Association Between Baseline Brain Volume and Long-term Cognition in Patients With Relapsing Multiple Sclerosis. Poster presented at the 8th European Academy of Neurology (EAN) Congress, Vienna, Austria, Jun 25 – 28, 2022. Available at!contentsessions/62231.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally